Zoar Ltd has successfully completed its merger with Impact Biomedical Inc., a significant milestone that will allow the company to trade publicly on the NYSE American under the ticker symbol ZOAR starting November 18, 2026.
This merger, which was finalized on November 17, 2026, is expected to enhance Zoar's visibility in the pharmaceutical industry and provide new growth opportunities. Dr. Kanans Visvanats, the founder and CEO of Zoar, expressed optimism about the merger, stating, "Completing this business combination and listing on NYSE American is an important milestone for Zoar and for the customers and partners who have supported us since our founding in 2012."
Background
Zoar Ltd, classified under the SIC code 2834 for Pharmaceutical Preparations, focuses on the development and manufacturing of complex active pharmaceutical ingredients (APIs) and intermediates. The company is based in Kowloon, Hong Kong, and operates globally, supplying products to customers in over 35 countries. As of November 18, 2026, Zoar's ordinary shares are expected to commence trading on the NYSE American.
What the Filing Says
The recent SEC filing confirms the completion of the business combination, stating, "On November 17, 2026, Zoar Limited consummated the previously announced business combination... involving the Company, Impact Biomedical Inc., Zoar Labs Limited, Dr Ashleys Nevada Sub, Inc. and Kanas Visvanats." The filing indicates that each share of Impact common stock was converted into one Zoar ordinary share as part of the merger.
Impact
This merger will significantly impact both Zoar and its competitors in the pharmaceutical preparations sector. With the merger, Zoar aims to leverage its enhanced market presence to pursue growth strategies, including expanding its product offerings in orphan drug APIs. The merger was approved by Impact Biomedical Inc.'s stockholders at a special meeting held on November 13, 2026.
What's Next
The filing does not say what happens next, but the commencement of trading on the NYSE American marks a new chapter for Zoar Ltd as it transitions into a public company.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





